Skip to main content
. Author manuscript; available in PMC: 2014 Nov 21.
Published in final edited form as: Sci Transl Med. 2014 May 21;6(237):237ra68. doi: 10.1126/scitranslmed.3008639

Fig. 3. Merlin-negative mesothelioma cells are especially sensitive to VS-4718 in vivo.

Fig. 3

A) Bar graph depicting average tumor weights from MM87 orthotopic lung tumor model treated with VS-4718, as indicated. Data are presented as mean ± SD (N=10). ****p<0.0001 (Mann-Whitney test). B) Dot plot of tumor volumes in MM87 IP xenograft model treated with VS-4718, as indicated. Black lines represent the mean, whiskers depict 25% and 75% of the distribution, N=5. **p=0.0079 (Mann-Whitney test). C) Relative pFAK-Y397 levels measured by ELISA in tumor samples from (B). Black lines represent the mean, whiskers depict 25% and 75% of the distribution, N=5. *p=0.0159 (Mann-Whitney test). D) Tumor volumes from Merlin-positive human MPM PDX model treated with VS-4718 at 50 mg/kg p.o. BID. Data are presented as mean ± SEM (n=10). Tumor weights on day 42 are not significantly different (ns). p=0.19 (unpaired t-test with Welch’s correction). E) Tumor volumes from a Merlin-negative human MPM PDX model treated with: control (blue), VS-4718 at 50 mg/kg p.o. BID (purple), cisplatin at 4 mg/kg i.p. (once every 7 days) and pemetrexed at 75 mg/kg i.p. (once daily, 5 days on, 2 days off) for 14 days (green), cisplatin at 4 mg/kg i.p. (once every 7 days) and pemetrexed at 75 mg/kg i.p. (once daily, 5 days on, 2 days off) for 14 days followed by VS-4718 at 50 mg/kg p.o. BID started on day 16 (red). Data are presented as mean ±SEM (N=10). **p= 0.0089 (Mann-Whitney test); *p=0.035 (unpaired t-test with Welch’s correction).